inside the rapidly evolving industry of oncology exploration, correct and efficient mutation screening is essential for creating qualified therapies. The KRAS companies Platform plays a pivotal role On this landscape by giving in depth options for KRAS mutation profiling and analysis. KRAS mutations, located in close to 95% of RAS-associated oncoge